Zobrazeno 1 - 10
of 112
pro vyhledávání: '"Wungki Park"'
Autor:
James Harding, Allison Richards, Dae Won Kim, Wungki Park, Kevin Soares, Danny Khalil, Olca Basturk, Mark Donoghue, William Jarnagin, Darren Cowzer, Ghassan Abou-Alfa, Fergus Keane, Hulya Sahin Ozkan, Vasilisa Rudneva, Bruno A Costa, Zeyneb Tarcan, Eileen M O’Reilly
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/20f72e96366d4b2f86a1fdb822d30632
Autor:
Edward Christopher Dee, Victor C. Ng, Eileen M. O’Reilly, Alice C. Wei, Stephanie M. Lobaugh, Anna M. Varghese, Melissa Zinovoy, Paul B. Romesser, Abraham J. Wu, Carla Hajj, John J. Cuaron, Danny N. Khalil, Wungki Park, Kenneth H. Yu, Zhigang Zhang, Jeffrey A. Drebin, William R. Jarnagin, Christopher H. Crane, Marsha Reyngold
Publikováno v:
Journal of Clinical Medicine, Vol 13, Iss 9, p 2631 (2024)
Introduction: The rate of isolated locoregional recurrence after surgery for pancreatic adenocarcinoma (PDAC) approaches 25%. Ablative radiation therapy (A-RT) has improved outcomes for locally advanced disease in the primary setting. We sought to ev
Externí odkaz:
https://doaj.org/article/e5daf592d8314f32af09518b56a1863b
Autor:
Fergus Keane, Raazi Bajwa, Pier Selenica, Wungki Park, Michael H. Roehrl, Jorge S. Reis-Filho, Diana Mandelker, Eileen M. O’Reilly
Publikováno v:
npj Precision Oncology, Vol 7, Iss 1, Pp 1-8 (2023)
Abstract Poorly differentiated pancreatic neuroendocrine tumors (PDNEC), are a subtype of pancreatic cancer encompassing both small cell and large cell neuroendocrine carcinoma subtypes, and are characterized as distinct in terms of biology and progn
Externí odkaz:
https://doaj.org/article/190db58c7ab44bb79fe3e0deef0cefb6
Autor:
Ignacio Garrido-Laguna, Asaf Maoz, Wungki Park, Abdul Rafeh Naqash, Vaia Florou, Breelyn Wilky, Jonathan Trent, Umang Swami, Garrett Frampton, Heloisa P Soares, Sonam Puri, Aik Choon Tan, Charalampos S Floudas, Carter Norton, Ethan S Sokol, Peter Hosein, Gilberto de Lima Lopes
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 8 (2023)
Background Pembrolizumab is FDA approved for tumors with tumor mutational burden (TMB) of ≥10 mutations/megabase (mut/Mb). However, the response to immune checkpoint inhibitors (ICI) varies significantly among cancer histologies. We describe the la
Externí odkaz:
https://doaj.org/article/206cd2d9903d405d9e63f577bd3f9aea
Stereotactic ablative radiation for pancreatic cancer on a 1.5 Telsa magnetic resonance-linac system
Autor:
Kathryn R. Tringale, Neelam Tyagi, Marsha Reyngold, Paul B. Romesser, Abraham Wu, Eileen M. O'Reilly, Anna M. Varghese, Paola Godoy Scripes, Danny N. Khalil, Wungki Park, Kenneth Yu, Christopher H. Crane
Publikováno v:
Physics and Imaging in Radiation Oncology, Vol 24, Iss , Pp 88-94 (2022)
Purpose: Ablative radiation therapy (A-RT) appears to improve outcomes in locally advanced pancreatic cancer (LAPC) yet requires solutions for respiratory and digestive motion. We report outcomes of A-RT for pancreatic cancer using 1.5 T MR-adaptive
Externí odkaz:
https://doaj.org/article/9ae9587aa5c341c781572daaee045566
Publikováno v:
Cancers, Vol 15, Iss 11, p 2955 (2023)
Pancreatic ductal adenocarcinoma (PDAC) is projected to become the second leading cause of cancer-related death in the US by 2030, despite accounting for only 5% of all cancer diagnoses. Germline gBRCA1/2-mutated PDAC represents a key subgroup with a
Externí odkaz:
https://doaj.org/article/aa0d58de7e47437589974336e929f7e3
Autor:
Davide Bedognetti, Michele Ceccarelli, Lorenzo Galluzzi, Rongze Lu, Karolina Palucka, Josue Samayoa, Stefani Spranger, Sarah Warren, Kwok-Kin Wong, Elad Ziv, Diego Chowell, Lisa M. Coussens, Daniel D. De Carvalho, David G. DeNardo, Jérôme Galon, Howard L. Kaufman, Tomas Kirchhoff, Michael T. Lotze, Jason J. Luke, Andy J. Minn, Katerina Politi, Leonard D. Shultz, Richard Simon, Vésteinn Thórsson, Joanne B. Weidhaas, Maria Libera Ascierto, Paolo Antonio Ascierto, James M. Barnes, Valentin Barsan, Praveen K. Bommareddy, Adrian Bot, Sarah E. Church, Gennaro Ciliberto, Andrea De Maria, Dobrin Draganov, Winson S. Ho, Heather M. McGee, Anne Monette, Joseph F. Murphy, Paola Nisticò, Wungki Park, Maulik Patel, Michael Quigley, Laszlo Radvanyi, Harry Raftopoulos, Nils-Petter Rudqvist, Alexandra Snyder, Randy F. Sweis, Sara Valpione, Roberta Zappasodi, Lisa H. Butterfield, Mary L. Disis, Bernard A. Fox, Alessandra Cesano, Francesco M. Marincola, Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Groups
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-23 (2019)
Abstract Tumor immunology has changed the landscape of cancer treatment. Yet, not all patients benefit as cancer immune responsiveness (CIR) remains a limitation in a considerable proportion of cases. The multifactorial determinants of CIR include th
Externí odkaz:
https://doaj.org/article/864f25d06ad04690a4ef2014434f0547
Autor:
Laura Carter, Andrea Wang-Gillam, Johanna Bendell, Wungki Park, Wells Messersmith, Drew Rasco, Lei Zhou, Jean-Marie Bruey, Beatrice Ferguson, Jakob Dupont, Marya Chaney, Johann De Bono, David Nickle, Anna Galkin
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/4c3856eeaeb64d86ae0c6a78be6a0f14
Autor:
Muhammad Husnain, Wungki Park, Juan Carlos Ramos, Thomas E. Johnson, Joseph Chan, Arvind Dasari, Raja Mudad, Peter J. Hosein
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-5 (2018)
Abstract Background Immune checkpoint inhibitors (CPIs) have shown promising results in many solid tumors. There are limited data on the safety and efficacy of these drugs in HIV infected patients as they have traditionally been excluded from CPIs cl
Externí odkaz:
https://doaj.org/article/28886b086c754a4c8c3f2ef2e1f0bcbf
Autor:
Davide Bedognetti, Michele Ceccarelli, Lorenzo Galluzzi, Rongze Lu, Karolina Palucka, Josue Samayoa, Stefani Spranger, Sarah Warren, Kwok-Kin Wong, Elad Ziv, Diego Chowell, Lisa M. Coussens, Daniel D. De Carvalho, David G. DeNardo, Jérôme Galon, Howard L. Kaufman, Tomas Kirchhoff, Michael T. Lotze, Jason J. Luke, Andy J. Minn, Katerina Politi, Leonard D. Shultz, Richard Simon, Vésteinn Thórsson, Joanne B. Weidhaas, Maria Libera Ascierto, Paolo Antonio Ascierto, James M. Barnes, Valentin Barsan, Praveen K. Bommareddy, Adrian Bot, Sarah E. Church, Gennaro Ciliberto, Andrea De Maria, Dobrin Draganov, Winson S. Ho, Heather M. McGee, Anne Monette, Joseph F. Murphy, Paola Nisticò, Wungki Park, Maulik Patel, Michael Quigley, Laszlo Radvanyi, Harry Raftopoulos, Nils-Petter Rudqvist, Alexandra Snyder, Randy F. Sweis, Sara Valpione, Roberta Zappasodi, Lisa H. Butterfield, Mary L. Disis, Bernard A. Fox, Alessandra Cesano, Francesco M. Marincola, Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Groups
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-2 (2019)
Following publication of the original article [1], the author reported that an author name, Roberta Zappasodi, was missed in the authorship list.
Externí odkaz:
https://doaj.org/article/8274c82abc7148b581d8fa04cb981e68